The Hospital for Sick Children. "Newly uncovered mechanism could drive next-gen cystic fibrosis treatments." ScienceDaily. ScienceDaily, 13 March 2025. <www.sciencedaily.com / releases / 2025 / 03 / ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Studying how proteins cluster and organize themselves at the cell membrane could pave the way for innovative cystic fibrosis ...
A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator ...
The CFTR Protein Distribution Core offers high-quality, full-length recombinant cystic fibrosis transmembrane conductance regulator (CFTR) proteins expressed in and purified from mammalian cells. Wild ...
A new research project focusing on rare genetic mutations that are linked to cystic fibrosis just received $600,000 in ...
Cystic fibrosis (CF) is a life-threatening autosomal recessive disease affecting over 160,000 people worldwide. CF is caused by loss-of-function mutations in the CF transmembrane conductance regulator ...
Researchers introduced functional porosomes into the plasma membrane of CFTR mutant cells to demonstrate that porosome reconstitution normalizes mucus secretion more than twice as effective than ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
Guggenheim initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $45 price target The firm has a positive view of NBD1 ...
A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell ...
A recent retrospective study published in CHEST(Opens in a new window) evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use on pregnancy outcomes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback